Skip to content
1 min left
0% read
Character Biosciences logo

Character Biosciences

Technology Company
San Francisco, California, USA
Founded 2019
48

Character Biosciences is a precision medicine company transforming drug development for progressive, polygenic diseases, beginning with ophthalmology.

Share:

Character Biosciences

Character Biosciences is a precision medicine company transforming drug development for progressive, polygenic diseases, beginning with ophthalmology. Our mission is to identify the genetic and molecular drivers of disease progression so we can develop targeted therapies for patients who urgently need them.

We've built one of the most comprehensive resources in age-related eye diseases by partnering with over 150 ophthalmology clinics to integrate genetics with longitudinal clinical and imaging data. This deep phenotyping approach enables us to reclassify complex diseases like age-related macular degeneration (AMD) into genetically defined subtypes, unlocking novel therapeutic targets and optimizing patient selection for clinical trials.

Character Bio's AI-powered platform combines genomics, multi-modal data, and machine learning to discover and develop therapies that are more precise and more effective. Our lead programs, CTX114 and CTX203, are advancing toward clinical trials and are designed to slow or prevent vision loss in AMD patients.

We are committed to delivering a new generation of precision medicines to treat and ultimately cure age-related blindness.

Frequently Asked Questions About Character Biosciences

Character Biosciences is an infrastructure company. Character Biosciences is a precision medicine company transforming drug development for progressive, polygenic diseases, beginning with ophthalmology.

Character Biosciences is a precision medicine company transforming drug development for progressive, polygenic diseases, beginning with ophthalmology. Our mission is to identify the genetic and molecular drivers of disease progression so we can develop targeted therapies for patients who urgently ne.

Character Biosciences has been operating since 2019. You can verify their legitimacy through their official website and social media presence.

Character Biosciences operates in the infrastructure sector of the cryptocurrency industry. Compare Character Biosciences with other infrastructure companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using Character Biosciences, research their track record (operating since 2019), verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. Character Biosciences is based in San Francisco, California, USA, has been operating since 2019. Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

Character Biosciences is based in San Francisco, California, USA, North America, with offices in San Francisco, California, USA, Jersey City, New Jersey, USA, San Carlos, California, USA.

Character Biosciences was founded in 2019. The company currently has 48 employees.

Character Biosciences Details

Character Biosciences Offices (9)

Character Biosciences Tags

More About Character Biosciences

Work Model Details
Employees work from physical offices.

Latest from Academy

Buy Verge Now or Wait Until Privacy Regulations Shift

Buy Verge Now or Wait Until Privacy Regulations Shift

XVG is trading near a multi-month low at $0.004285, down 17.67% over the last month. The privacy coin space has already felt regulatory pressure with several exchanges facing government scrutiny. Verge's case is different though. Verge has compensated users with privacy options rather than forcing privacy features on them. As regulators continue to stack the deck against privacy coins, Verge's argument for usability may become even more attractive.

11m
Why AIOZ Network Keeps Outperforming While Other DePINs Bleed

Why AIOZ Network Keeps Outperforming While Other DePINs Bleed

DePIN overall has declined 40% of its total market cap Q4 2025 to Q1 2026. Filecoin is trading at a fraction of its 2021 all-time highs. Theta has plateaued in node growth. Livepeer's demand for transcoding services has stagnated. But one project has been hard to miss in a sea of moving targets: AIOZ Network has continued to hit product milestones, crossed over 30,000 nodes from more than 100 countries, and had Kova Network, NakamotoGames, and other projects integrate with its network.

9m
Celestia Built the Modular Stack and Nobody's Using It Yet

Celestia Built the Modular Stack and Nobody's Using It Yet

The dominant narrative around Celestia right now is generational infrastructure bet. Some modular blockchain scaling tech that will reprice when everyone finally figures it out. Reality paints a different picture. TIA is trading 98.6% below its all-time high of $20.85. Celestia is generating $43.73 per day in network fees. Over 50% of all data being committed to the protocol comes from one rollup. The disconnect between "could use it" and "do use it" is the core narrative for TIA right now.

9m